Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective hard but unsuccessfully to produce a single therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV have been closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of my past few shares. The 1st CytoDyn post of mine, “CytoDyn: What In order to Do When It’s Too Good To Be True?”, set out all of the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such a highly promotional picture in the Uptick Newswire job interview that I came away with an inadequate viewpoint of the business.

Irony of irony, my poor opinion of the company has grown steadily, although the disappointment has not been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger at the moment still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the treatment as well as prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity in HIV- infected subjects. Today’s transaction of $3.5 million transfers ownership of the know-how and connected intellectual property coming from Progenics to CytoDyn, and also approximately twenty five million mg of majority drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 zillion) and the first new drug application approval ($five million), and even royalty payments of five percent of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many therapies and numerous indications, it has this individual remedy as well as a “broad pipeline of indications” since it puts it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely beneficial therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an active business with diverse interests albeit centered on leronlimab, multiple illness types, multiple publications and multiple delivering presentations.

Could all of it be smoke cigarettes and mirrors? That’s a question I’ve been asking myself with the really start of my interest in this particular organization. Judging by way of the multiples of thousands of diverse remarks on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m a lot from alone in this particular question.

CytoDyn is a classic battleground, or maybe some could say cult stock. Its adherents are fiercely protective of its prospects, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *